Strides Pharma Science Limited has announced that the Scheme of Demerger involving Arco Lab Private Limited and Pivot Path Private Limited became effective from June 1, 2026. The demerger involves the transfer of the identified business of Arco Lab to Pivot Path. This development follows the approval granted by the Hon’ble National Company Law Tribunal (NCLT), Bengaluru Bench.

The company received the certified copy of the NCLT Order approving the Scheme of Demerger on May 25, 2026. Subsequently, the participating entities, Arco Lab and Pivot Path, filed the certified true copy of the order with the Registrar of Companies. This filing finalized the procedural requirements, rendering the scheme effective from the stipulated date.

Key Details of the Demerger

The following table summarizes the critical dates and entities involved in the Scheme of Demerger:

The Scheme of Demerger was approved by the NCLT, Bengaluru Bench, facilitating the transfer of the identified business from Arco Lab to Pivot Path. The intimation regarding the effective date was submitted to BSE Limited and The National Stock Exchange of India Limited under Regulation 30 of the SEBI Listing Regulations. Manjula Ramamurthy, Company Secretary of Strides Pharma Science Limited, signed the regulatory filing.

Strides Pharma Science Limited has confirmed that its promoters and promoter group did not encumber any shares during the financial year ended March 31, 2026. The disclosure, submitted to the stock exchanges, assures investors that no new pledges or charges were created on the promoter holdings, other than those already reported.

The declaration was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires listed companies to inform the exchanges if promoters have pledged their shares as collateral, a move that can signal financial stress or risk for shareholders.

Pronomz Ventures LLP, representing the promoters and promoter group, communicated the status to the National Stock Exchange of India Limited and BSE Limited. The firm confirmed that the shareholding remained free from fresh encumbrances throughout FY26.

The filing was signed by Chandrappa Seetharamaiah, Designated Partner of Pronomz Ventures LLP. The document was submitted to the exchanges on April 7, 2026, for their information and records.